Premium
Light responsive hybrid nanofibres for on‐demand therapeutic drug and cell delivery
Author(s) -
Li YanFang,
SlemmingAdamsen Peter,
Wang Jing,
Song Jie,
Wang Xueqin,
Yu Ying,
Dong Mingdong,
Chen Chunying,
Besenbacher Flemming,
Chen Menglin
Publication year - 2017
Publication title -
journal of tissue engineering and regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 72
eISSN - 1932-7005
pISSN - 1932-6254
DOI - 10.1002/term.2169
Subject(s) - drug delivery , hela , electrospinning , extracellular matrix , nanotechnology , chemistry , biomedical engineering , self healing hydrogels , on demand , biophysics , cancer cell , viability assay , adhesion , materials science , cell , polymer , cancer , polymer chemistry , biochemistry , medicine , multimedia , organic chemistry , biology , computer science
Smart materials for on‐demand delivery of therapeutically active agents are challenging in pharmaceutical and biomaterials science. In the present study, we report hybrid nanofibres capable of being reversibly controlled to pulsatile deliver both therapeutic drugs and cells on‐demand of near‐infrared (NIR) light. The nanofibres, fabricated by co‐electrospinning of poly ( N ‐isopropylacrylamide), silica‐coated gold nanorods and polyhedral oligomeric silsesquinoxanes have, for the first time, demonstrated rapid, reversible large‐volume changes of 83% on‐demand with NIR stimulation, with retained nanofibrous morphology. Combining with the extracellular matrix‐mimicking fibrillary properties, the nanofibres achieved accelerated release of model drug or cells on demand with NIR triggering. The release of the model drug doxorubicin demonstrated normal anti‐cancer efficacy by reducing the viability of human cervical cancer HeLa cells by 97% in 48 h. In parallel, the fibres allowed model cell NIH3T3 fibroblast entrapment, adhesion, proliferation, differentiation and, upon NIR irradiation, cell release with undisturbed cellular function. Copyright © 2016 John Wiley & Sons, Ltd.